Switching from Zoledronic Acid to Denosumab for Bone Modification Therapy in Patients with Malignant Tumors and Renal Insufficiency: A Retrospective Case Series and Literature Review
Abstract
Abstract Introduction: Zoledronic acid is a common treatment for bone metastases in malignancies, but it is contraindicated in patients with severe renal insufficiency due to its nephrotoxicity. Dose adjustments are necessary for those with mild-to-moderate renal insufficiency. Denosumab is not metabolized by the kidney, hence providing an alternative for patients who are unable to receive zoledronic acid due to nephrotoxicity. Case Presentation: In this study, we retrospectively reviewed 4 patient cases with bone metastases from solid tumors (two breast cancer, one prostate cancer, and one lung cancer), all developed nephrotoxicity during zoledronic acid treatment and subsequently switched to denosumab. Renal function either improved or remained stable following the switch. And a review of the literature related to denosumab was conducted. Conclusion: Patients with abnormal renal function, BRCA1 mutations, or those at high risk of developing skeletal-related events may benefit from denosumab over zoledronic acid. During denosumab treatment in patients with renal dysfunction, attention should be paid to the occurrence of hypocalcemia.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.